Kazakhstan vs Saint Kitts and Nevis: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Kazakhstan
0.2%
in 2024
Saint Kitts and Nevis
0.2%
in 2024
Kazakhstan rank
98th
Saint Kitts and Nevis rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Kazakhstan
- Saint Kitts and Nevis
How they compare
Kazakhstan currently reports 0.2% against 0.2% in Saint Kitts and Nevis, a difference of 0.0%.
Across all 10 years both countries report, Saint Kitts and Nevis has been ahead every year.
Kazakhstan ranks 98th and Saint Kitts and Nevis ranks 98th of 246 countries.
Saint Kitts and Nevis has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Kazakhstan | Saint Kitts and Nevis | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.2% | 0.3% | 0.1% | Saint Kitts and Nevis |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Kazakhstan or Saint Kitts and Nevis?
- Kazakhstan, at 0.2% against 0.2% in Saint Kitts and Nevis as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Kazakhstan and Saint Kitts and Nevis?
- 0.0%, with Kazakhstan ahead.
- How many years of comparable data are there for Kazakhstan and Saint Kitts and Nevis?
- 10 years are reported by both, from 2015 to 2024.
- How do Kazakhstan and Saint Kitts and Nevis rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Kazakhstan ranks 98th and Saint Kitts and Nevis ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.